An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy-Reference-Cited by-同舟云学术

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy

Published:2012-06-06 Issue:24 Volume:118 Page:6063-6071
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Antonarakis Emmanuel S.,Keizman Daniel,Zhang Zhe,Gurel Bora,Lotan Tamara L.,Hicks Jessica L.,Fedor Helen L.,Carducci Michael A.,De Marzo Angelo M.,Eisenberger Mario A.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference36 articles.

1. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths;Siegel;CA Cancer J Clin.,2011

2. Era-specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer;Han;J Urol.,2001

3. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome;Zietman;Int J Radiat Oncol Biol Phys.,1995

4. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results;Roehl;J Urol.,2004

5. CALGB 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease;Eastham;Urology.,2003

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differences in the expression of the phosphatase PTP-1B in patients with localized prostate cancer with and without adverse pathological features;Frontiers in Oncology;2024-04-19

2. Prostate cancer radiogenomics reveals proliferative gene expression programs associated with distinct MRI-based hypoxia levels;Radiotherapy and Oncology;2023-11

3. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells;Nature Cancer;2023-07-17

4. Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study;Cancer Chemotherapy and Pharmacology;2022-10-28

5. New gold(III) chlorophenyl terpyridine complex: Biomolecular interactions and anticancer activity against human oral squamous cell carcinoma;Applied Organometallic Chemistry;2022-10-24